25
KIT
Beyond the retrospective and current
view on glucose values and trend
estimations, it will indicate the risk
of a hypo in the next 30 minutes
and continuously forecast how
glucose will develop in the next two
hours. In addition, it will estimate
the risk of nocturnal hypos. "This
empowers users to be in control
and take preventive decisions to
adjust their therapy and pre-empt
complications", stated Professor Lutz
Heinemann (Duesseldorf, Germany),
continuing: "Using the potential of
predictive algorithms contributes to
less troubleshooting and unforeseen
glucose excursions, less fear of
hypos and less diabetes burden."
The evaluation of the Accu-Chek
SmartGuide Predict app showed
that all advanced predictive features
exceeded the high performance
requirements.3
Closing the event, Dr. Marcel
Gmuender, Global Head of Roche
Diabetes Care "We are very
excited to present these positive
study results of our innovative
and differentiating Accu-Chek
SmartGuide CGM device for the first
time. Providing users with predictive
capabilities will empower them to
proactively adapt their therapy so
they can maintain optimal glycemic
control and prevent dangerous
short- and long-term complications.
We know from recent research that
glucose predictions provide people
with diabetes with invaluable insights
to navigate the complexities of the
disease. This is one element that can
help to lower the burden of daily
diabetes management."4
Founded in 1896 in Basel,
Switzerland, as one of the first
industrial manufacturers of branded
medicines, Roche has grown into
the world's largest biotechnology
company and the global leader in
in-vitro diagnostics. Roche Diabetes
Care has been pioneering innovative
diabetes technologies and services
for more than 40 years.
83% of our study
participants liked
or very much liked
the Accu-Chek
SmartGuide CGM
device and about
80% liked or very
much liked the
app design
~ Prof Mader
Sources:
1 Fang, M. J Gen Intern Med 35,
1427-1434 (2020) | 2 Sims, EK et al.,
Nat Med. 2021 Jul;27(7):1154-1164. | 3
Roche Data on le; data presented at
Roche-sponsored symposium at the
17th ATTD International Conference,
March 6, 2024, Florence, Italy
(symposium recording to be available
here) | 4 Ehrmann, D. et al, European
association for the study of diabetes,
2023, Short-oral: "Anticipated
reduction in hypoglycaemia fear and
diabetes distress from increasing
the glucose prediction of current
CGM algorithms", publication
submitted JDST.
Caption.
EDITOR'S COMMENT:
We'll report further on this
product and its launch in the
next issue of the magazine,
out at the end of September.